Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine. A phase-II study

Journal of Neuro-Oncology

Volumn 37, Issue 2, 1998, Pages 155-160

  Hildebrand, J ^a   De Witte, O ^a   Sahmoud, T ^b  

^a ERASME HOSPITAL   (Belgium)

^b EORTC DATA CENTER   (Belgium)

Author keywords

Anaplastic astrocytoma; BCNU; Dibromodulcitol; Glioblastoma; Procarbazine

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; MITOLACTOL; PROCARBAZINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MALE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PROGNOSIS; REMISSION; SURVIVAL TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARMUSTINE; FEMALE; GLIOBLASTOMA; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; MITOLACTOL; NEOPLASM RECURRENCE, LOCAL; PROCARBAZINE; SURVIVAL ANALYSIS;

EID: 0031882610     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005952925378     Document Type: Article

References (14)

1. Fine HA, Dear KBG, Loeffler JS et al.: Meta-analysis of radiation therapy with and without chemotherapy for malignant glioma in adults. Cancer 71: 2585-2597, 1993
2. Institoris L, Horvath IP, Pethes G: Some characteristic features of the biotransport of the cytostatic agent 1,6-dibromo-1,6-di-deoxy-dulcitol. Int J Cancer 2: 21-25, 1967
3. Hidvégi EJ, Lonai P, Holland J et al.: The effect of mannitolmyleran and two new dibromo-hexitols on the metabolic activities of nucleic acids and proteins. J Biochem Pharmacol 16: 2143-2153, 1967
4. Hidvégi EJ, Perlaky A, Fonagy L et al.: Combination of dibromodulcitol with X-irradiation increases in life span of mice bearing experimental brain tumours XI-(abstract). In: 14th International Cancer Congress, Budapest, Hungary: Abstracts, vol 1. Budapest: akadémiai Kiado 47, 1986
5. Pulst SM, Deen DF: Potentiation of BCNU-induced cytotoxicity and sister chromatid exchanges by dibromodulcitol in vitro. Anticancer Res 10: 1647-1650, 1990
6. Afra D, Kocsis B, Kerpel-Fronius S, Eckhardt S: Dibromodulcitol-based combined postoperative chemotherapy of malignant astrocytomas and glioblastomas. J Neurooncol 4: 65-70, 1986
7. Hildebrand J, Sahmoud T, Mignolet F et al.: Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 44: 1479-1483, 1994
8. MacDonald DR, Cascino TL, Schold SC, Cairncross JG: Response criteria for phase II studies of supratentorial malignant gliomas. J Clin Oncol 8: 1277-1280, 1990
9. Armitage P: Statistical Methods in Medical Research. Blackwell Scientific Publications, Oxford 3rd Edition, 1971
10. WHO off-set publication nr 48, Geneva, 1979
11. Georges P, Przedborski S, Brotchi J et al.: Effect of HeCNU in malignant supratentorial gliomas - a phase II study. J Neuro-oncol 6: 211-219, 1988
12. Frenay M, Giroux B, Khoury S et al.: Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Euro J Cancer 27: 852-856, 1991
13. Hildebrand J: Treatment of primary brain tumours. In: Hildebrand J (ed) Management in Neuro-Oncology. Springer-Verlag, 3-22, 1992
14. Levin VA, Silver P, Hannigan J et al.: Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18: 321-324, 1990